NCT03918980View on ClinicalTrials.gov

Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064

PHASE1CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

August 18, 2016

Primary Completion Date

January 27, 2020

Study Completion Date

January 27, 2020

Conditions
Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis
Interventions
DRUG

LOU064

LOU064 will be administered as oral capsules in parts 1 to 6.

DRUG

Placebo

Matching placebo capsules will be administered in parts 1,2, 4 and 6.

Trial Locations (2)

14050

Novartis Investigative Site, Berlin

2333 CL

Novartis Investigative Site, Leiden

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY